Published in Vaccine Weekly, December 28th, 2005
Under terms of the Path agreement, Bioject will develop a needle-free, auto-disable, single dose cartridge injection system for use in immunization programs in the developing world. The agreement is divided into three stages covering activities from technical feasibility, country-level market assessments, fundraising, international public health clinical trials, scale-up for high-volume manufacturing, to full market implementation.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.